In simple words: This is a chemotherapy drug used to treat certain types of skin lymphoma and other blood cancers. It's given through an IV.

Romidepsin is an anticancer agent, a histone deacetylase (HDAC) inhibitor, supplied as a lyophilized powder for intravenous infusion. It is used to treat cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL).

Example 1: A patient with cutaneous T-cell lymphoma (CTCL) receives 14mg/m2 of romidepsin on days 1, 8, and 15 of a 28-day cycle via IV infusion, as part of their chemotherapy treatment., A patient diagnosed with peripheral T-cell lymphoma (PTCL), after failing other chemotherapy regimens, begins treatment with romidepsin at a dosage determined by their body surface area, administered intravenously on a specific schedule., A patient with relapsed CTCL receives romidepsin IV infusion, with the dosage carefully calculated and adjusted based on their response to the treatment and any adverse effects.

Documentation should include the diagnosis (CTCL or PTCL), the dosage administered (in mg), the date of administration, the route of administration (IV), and any adverse reactions.